| Name | Title | Contact Details |
|---|
EvenUp is a legal technology company based in San Francisco, founded in late 2019. The company focuses on enhancing personal injury law through AI-driven solutions. With support from notable venture capital firms, EvenUp aims to improve transparency and efficiency in personal injury litigation by integrating machine learning with legal expertise. The company offers a Claims Intelligence Platform™, which automates workflows, creates documents, and provides business insights to optimize law firm performance. Its proprietary Piai™ AI Model analyzes medical records and historical case data to predict case valuations. EvenUp provides end-to-end support for law firms, assisting from case intake to resolution while reducing manual effort. EvenUp serves a diverse range of personal injury law firms, from top trial attorneys to large injury practices. The company is recognized for its commitment to innovation in the legal field, including initiatives like the 2025 Personal Injury Pioneer Awards. With a focus on addressing systemic inequities in injury compensation, EvenUp combines technological advancements with a human-centric approach to empower legal professionals and their clients.
Accent Portraits By Diana is a San Juan Capistrano, CA-based company in the Business Services sector.
Alsaker Corporation is a Spokane, WA-based company in the Business Services sector.
The Schooner Group is a West Haven, CT-based company in the Business Services sector.
Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering. The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.